Clinical trial
Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney…
NCT00044720 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00044720 |
|---|---|
| Title | Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients |
| Official title | An Open-label, Concentration Controlled, Randomized, 12 Month Study of Prograf + Rapamune + Cor |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Chronic Kidney Failure, Graft vs Host Disease, Kidney Transplantation |
| Intervention type | Drug |
| Interventions | Rapamune |
| Enrollment | 484 |
| Primary completion | Jul 1, 2005 |
| Completion | Jul 1, 2005 |
| First posted | Sep 6, 2002 |
| Last update posted | Aug 18, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: